Successful treatment of cardiac involvement in dermatomyositis with rituximab

Zahi Touma, Thurayya Arayssi, Lina Kibbi, Abdel Fattah Masri

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25 year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-α. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.

Original languageEnglish
Pages (from-to)334-337
Number of pages4
JournalJoint Bone Spine
Volume75
Issue number3
DOIs
Publication statusPublished - May 2008
Externally publishedYes

Fingerprint

Dermatomyositis
Myositis
Antirheumatic Agents
Muscle Weakness
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Heart Diseases
Adrenal Cortex Hormones
B-Lymphocytes
Therapeutics
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Inflammation
Rituximab

Keywords

  • Cardiac disease
  • Dermatomyositis
  • Rituximab

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Successful treatment of cardiac involvement in dermatomyositis with rituximab. / Touma, Zahi; Arayssi, Thurayya; Kibbi, Lina; Masri, Abdel Fattah.

In: Joint Bone Spine, Vol. 75, No. 3, 05.2008, p. 334-337.

Research output: Contribution to journalArticle

Touma, Zahi ; Arayssi, Thurayya ; Kibbi, Lina ; Masri, Abdel Fattah. / Successful treatment of cardiac involvement in dermatomyositis with rituximab. In: Joint Bone Spine. 2008 ; Vol. 75, No. 3. pp. 334-337.
@article{7fd2c97d6cb74cec834bff16279bde14,
title = "Successful treatment of cardiac involvement in dermatomyositis with rituximab",
abstract = "Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25 year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-α. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.",
keywords = "Cardiac disease, Dermatomyositis, Rituximab",
author = "Zahi Touma and Thurayya Arayssi and Lina Kibbi and Masri, {Abdel Fattah}",
year = "2008",
month = "5",
doi = "10.1016/j.jbspin.2007.05.011",
language = "English",
volume = "75",
pages = "334--337",
journal = "Revue du Rhumatisme (English Edition)",
issn = "1169-8446",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Successful treatment of cardiac involvement in dermatomyositis with rituximab

AU - Touma, Zahi

AU - Arayssi, Thurayya

AU - Kibbi, Lina

AU - Masri, Abdel Fattah

PY - 2008/5

Y1 - 2008/5

N2 - Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25 year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-α. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.

AB - Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25 year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-α. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.

KW - Cardiac disease

KW - Dermatomyositis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=42949138026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949138026&partnerID=8YFLogxK

U2 - 10.1016/j.jbspin.2007.05.011

DO - 10.1016/j.jbspin.2007.05.011

M3 - Article

C2 - 17988919

AN - SCOPUS:42949138026

VL - 75

SP - 334

EP - 337

JO - Revue du Rhumatisme (English Edition)

JF - Revue du Rhumatisme (English Edition)

SN - 1169-8446

IS - 3

ER -